PD-L1 Long(19-27)

A peptide cancer vaccine composed of a long peptide containing amino acids 19 through 27 (sequence FMTYWHLLNAFTVTVPKDL) derived from the tumor-associated antigen programmed death-ligand 1 (PD-L1). This investigational vaccine is designed to stimulate an immune response against cells expressing PD-L1, a protein commonly overexpressed on the surface of various tumor cells. By targeting this region of PD-L1, the vaccine aims to enhance anti-tumor immunity by promoting T cell recognition and destruction of cancer cells that evade immune surveillance via the PD-1/PD-L1 pathway[1]. The primary mechanism involves immunization with this specific peptide sequence to induce cytotoxic T lymphocyte responses against tumors expressing PD-L1.

Other names

long PD-L1 peptide vaccine